Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Imdelltra (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
• This summary is based on the review of one randomized controlled trial(s). ^[1]
• The Objective Response Rate (ORR) was 40% (97.5% CI, 29 to 52) in the 10-mg dose group and 32% (97.5% CI, 21 to 44) in the 100-mg dose group among patients with previously treated small-cell lung cancer.
• Median Progression-Free Survival (PFS) was 4.9 months (95% CI, 2.9 to 6.7) for the 10-mg dose group and 3.9 months (95% CI, 2.6 to 4.4) for the 100-mg dose group, with overall survival at 9 months estimated at 68% for the 10-mg group and 66% for the 100-mg group.
• Duration of response was maintained for at least 6 months in 59% of patients who achieved an objective response, with 55% of responses ongoing in the 10-mg group and 57% in the 100-mg group at data cutoff.
• Cytokine-release syndrome (CRS) was observed in 51% of patients in the 10-mg group and 61% in the 100-mg group, with grade 3 CRS occurring in 1% and 6% of patients, respectively. Decreased appetite occurred in 29% of patients in the 10-mg group and 44% in the 100-mg group; pyrexia occurred in 35% and 33% of patients in the 10-mg and 100-mg groups, respectively. Only 3% of patients discontinued tarlatamab due to treatment-related adverse events.
• There is no population types or subgroups information available in the reviewed studies.